Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
ViiV Healthcare, majority owned by GSK with Pfizer (NYSE:PFE) and Shionogi as shareholders, has expanded its voluntary licensing agreement with the Medicines Patent Pool (MPP) for cabotegravir to include HIV treatment patents.
The expanded agreement allows generic manufacturers to develop and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries, including least-developed, low-income, lower middle-income, and Sub-Saharan African nations. This builds upon their existing agreement for HIV prevention (PrEP).
Three generic manufacturers - Aurobindo, Cipla, and Viatris - will be able to produce generic versions of CAB LA for HIV treatment, following WHO's updated guidance recommending long-acting injectable cabotegravir + rilpivirine as a treatment option.
Pfizer (NYSE:PFE) and Astellas announced positive overall survival (OS) results from their Phase 3 EMBARK study of XTANDI® (enzalutamide) in combination with leuprolide for non-metastatic hormone-sensitive prostate cancer (nmHSPC).
The study demonstrated that XTANDI plus leuprolide achieved statistically significant and clinically meaningful improvement in overall survival compared to placebo plus leuprolide. While XTANDI monotherapy showed a favorable trend, it didn't reach statistical significance. The safety profile remained consistent with previous findings.
XTANDI is currently approved in over 80 countries and has treated more than 1.5 million men with advanced prostate cancer since 2012. The drug is notably the first androgen receptor inhibitor-based regimen to show survival benefits across multiple prostate cancer types.
ViiV Healthcare, majority owned by GSK with Pfizer (NYSE:PFE) and Shionogi as shareholders, presented new data at IAS 2025 demonstrating the effectiveness of its long-acting HIV treatments. The presentations focus on Vocabria + Rekambys (cabotegravir + rilpivirine LA) for HIV treatment and Apretude (cabotegravir long-acting) for HIV prevention.
Key highlights include the phase IIIb VOLITION study results, examining patient preferences for switching to long-acting injectables after achieving viral suppression with Dovato. Additional real-world effectiveness data from multiple studies (COMBINE-2, CARLOS, and BEYOND) demonstrate positive outcomes in various populations. Implementation studies PILLAR and EBONI show promising results for CAB LA in specific demographic groups.
The conference presentations also include new data from the Positive Perspectives wave three study, highlighting the impact of shared decision-making on treatment outcomes and patient satisfaction.
Pfizer (NYSE:PFE) announced positive topline results from the Phase 3 BASIS study of HYMPAVZI™ (marstacimab) for hemophilia A or B patients with inhibitors. The study demonstrated 93% reduction in annualized bleeding rate (ABR 1.39 vs 19.78; p < 0.0001) compared to on-demand treatment.
The trial involved 48 patients over a 12-month period, showing superiority across all bleeding-related secondary endpoints. HYMPAVZI offers a once-weekly subcutaneous injection with minimal preparation, targeting the Kunitz 2 domain of TFPI. The treatment was generally well-tolerated with no deaths or thromboembolic events reported.
This development is significant as approximately 20% of hemophilia A and 3% of hemophilia B patients develop inhibitors that render traditional factor replacement therapies ineffective.
Pfizer (NYSE:PFE) has announced its third-quarter 2025 dividend of $0.43 per share, maintaining its consistent dividend payment history. The dividend will be paid on September 2, 2025, to shareholders of record as of July 25, 2025. This marks Pfizer's 347th consecutive quarterly dividend, demonstrating the company's long-standing commitment to returning value to shareholders.
Pfizer (NYSE: PFE) has announced a conference call with investment analysts scheduled for August 5, 2025, at 10:00 a.m. EDT. The call will discuss the company's Second Quarter 2025 Performance Report, which will be released that morning.
Investors and the public can access the webcast through www.pfizer.com/investors. Participants can also join via phone using the following numbers: 800-456-4352 (US/Canada) or 785-424-1086 (International) with passcode "49385". The webcast replay and transcript will be available on Pfizer's website within 24 hours after the call and will remain accessible for at least 90 days.